# Trial to Evaluate the Efficacy and Safety of Tarceva and Capecitabine in Advanced Pancreatic Cancer Patients

> **NCT00873353** · PHASE2 · COMPLETED · sponsor: **Grupo Gallego de Investigaciones Oncologicas** · enrollment: 32 (actual)

## Conditions studied

- Metastatic Adenocarcinoma of the Pancreas

## Interventions

- **DRUG:** capecitabine + erlotinib

## Key facts

- **NCT ID:** NCT00873353
- **Lead sponsor:** Grupo Gallego de Investigaciones Oncologicas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2008-08
- **Final completion:** 2010-08
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2010-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00873353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00873353, "Trial to Evaluate the Efficacy and Safety of Tarceva and Capecitabine in Advanced Pancreatic Cancer Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00873353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*